For research use only. Not for therapeutic Use.
Galegenimab（Cat No.:I042095）is an investigational monoclonal antibody that targets the immune checkpoint receptor TIGIT (T-cell immunoreceptor with Ig and ITIM domains). TIGIT plays a role in suppressing T-cell activation and immune responses, particularly in the tumor microenvironment, allowing cancer cells to evade immune detection. By blocking TIGIT, galegenimab aims to enhance T-cell-mediated anti-tumor immunity and improve the effectiveness of cancer immunotherapies. It is being evaluated in clinical trials for various cancers, including non-small cell lung cancer (NSCLC) and melanoma, to assess its safety, efficacy, and potential as part of combination therapies.
| Catalog Number | I042095 |
| CAS Number | 2403683-24-7 |
| Purity | ≥95% |
